Long-term Efficacy and Safety Study With Oralgen Grass Pollen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00824447
Recruitment Status : Completed
First Posted : January 16, 2009
Last Update Posted : May 5, 2010
Information provided by:
Artu Biologicals

Brief Summary:
This study is designed to give additional information on the efficacy, safety and local effects (tolerability) of a dose of sublingual immunotherapy administered once a day, during a second grass pollen season.

Condition or disease Intervention/treatment Phase
Allergic Rhinoconjunctivitis Drug: Oralgen Other: placebo Phase 2 Phase 3

Detailed Description:

Allergy is one of the most common chronic diseases. Allergies to grass, weed, and tree pollens characteristically result in seasonal rhinitis symptoms commonly termed hay fever. The risk of developing asthma has been noted to be higher in patients with rhinitis than among the general population (10% versus 3.6%), confirming the fact that rhinitis is often the first step of the natural history of asthma.

Although several drugs effectively manage the symptoms of allergic rhinitis, conjunctivitis or asthma, they do not represent an etiopathogenic treatment of the considered diseases, and do not prevent the reappearance of the symptoms at the end of the treatment.

Immunotherapy is generally considered to be appropriate for patients in whom rhinitis symptoms cannot be controlled by an optimal medication regimen and avoidance of the allergens. At present, specific immunotherapy is the only therapy available that acts on the main cause of the allergic reaction by modifying or down-regulating the immune response.

Allergen immunotherapy is the administration of gradually increasing quantities of an allergen vaccine (extract) to an allergic subject, to reach a maintenance dose, which is effective in reducing the symptoms associated with exposure to the causative allergen.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 356 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, DB, Plcb Controlled, Multicentre, Multinat. Phase II/III FU Study to Assess Longterm Efficacy and Safety of 3 Different Dose Regimens of Oralgen® GrassPollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis
Study Start Date : August 2007
Actual Primary Completion Date : August 2008
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Bee pollen

Arm Intervention/treatment
Placebo Comparator: Placebo control
Placebo control
Other: placebo
placebo control
Other Name: Placebo control

Active Comparator: Grass pollen extract, twice weekly
Grass pollen extract, 9,500 BU, given twice weekly
Drug: Oralgen
allergen solution sublingually
Other Name: grasspollen extract

Active Comparator: Grass pollen extract daily
Grass pollen extract, 9,500 BU, given daily
Drug: Oralgen
allergen solution sublingually
Other Name: grasspollen extract

Active Comparator: Increased dose of grass pollen extract
Increased dose of grass pollen extract, 19,000 BU, given daily
Drug: Oralgen
allergen solution sublingually
Other Name: grasspollen extract

Primary Outcome Measures :
  1. Pollen Season Rhinoconjunctivitis Total Symptom Score [ Time Frame: site specific pollen season ]

Secondary Outcome Measures :
  1. Rescue medication usage [ Time Frame: one year ]
  2. Proportion of symptom-free days during the pollen season [ Time Frame: one year ]
  3. Rhinoconjunctivitis QoL Questionnaire [ Time Frame: one year ]
  4. Global evaluation of the efficacy by the patient [ Time Frame: one year ]
  5. Local and systemic tolerability and other adverse events, labor [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 51 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who meet the in and exclusion criteria for study AB0602 and successfully finished this study.
  • Patients who have given their written consent to participate in this study.
  • Patients who are willing to comply with the protocol and understand the information given.
  • Female patients of childbearing potential are eligible if they are not sexually active or if they use a medically accepted contraceptive method.
  • Negative urine pregnancy test if female at the end of the previous study.

Exclusion Criteria:

  • Pregnancy, breast-feeding / lactation or sexually active women of childbearing potential who are not using a medically accepted contraceptive method.
  • Patients who were non-compliant during study AB0602.
  • Patients with a past or current disease, which as judged by the investigator, may affect the patient's participation in or the outcome of this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00824447

  Show 39 Study Locations
Sponsors and Collaborators
Artu Biologicals
Principal Investigator: Dyonne van Duren, MD, PhD AMPHA Nijmegen, Toernooiveld 220, 6525EC, Nijmegen, The Netherlands
Principal Investigator: Knut Schaekel, MD, PhD Universitait Klinikum Carl Gustav Carus, Fetscherstrasse 74, SN 01307, Dresden, Germany
Principal Investigator: Iveta Kozlovska, MD, PhD Centrum Immunologie a allergologie, Pavla Horova 14, 84108 Bratislava, Slovak Republic

Responsible Party: Dr. F.F. Roossien, Artu Biologicals Europe B.V. Identifier: NCT00824447     History of Changes
Other Study ID Numbers: AB0602/1
2007-002477-31 ( EudraCT Number )
First Posted: January 16, 2009    Key Record Dates
Last Update Posted: May 5, 2010
Last Verified: May 2010

Keywords provided by Artu Biologicals:
long-term efficacy and safety
Oralgen® Grass Pollen
allergic rhinoconjunctivitis
Grass pollen extract

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases